BridgeMD
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
EU CTIS ID: 2024-514635-26-00
What this study is testing
1. The possibility of individualizing the treatment of malignant liver tumors in children by classifying them into different groups according to the stage of the disease; 2. The possibility of reducing the occurrence of treatment side effects without significantly affecting the cure rate; 3. Improvement of curability, where current therapy is still not effective enough; 4. Selection of the most effective methods of surgical treatment
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Clinically signs of Hepatoblastoma or Hepatocarcinoma (malignant tumors of the liver) + liver tumor; Age under 30; Signing informed consent to participate in the Study
You likely can't join if
- Previously or currently receiving chemotherapy treatment; Recurrence of the disease; Condition after organ transplantation; Uncontrolled generalized infection; Inability to conduct the Study in accordance with the Protocol; Other Associated Cancer; Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.